Hologic, Inc. (Nasdaq: HOLX), a global leader in women’s health, announced today that it has acquired Diagenode, a privately held, European developer and manufacturer of molecular diagnostic assays and epigenetics products, for approximately $159 million (130 million euros), subject to working capital and other customary closing adjustments. Diagenode offers more than 30 real-time PCR (polymerase chain reaction) tests that are CE-marked for the detection of bacteria, parasites and viruses involved in sexually transmitted infections, respiratory diseases, meningitis and gastroenteritis.
Read the full article: Hologic Acquires European Molecular Diagnostic Company Diagenode for Approximately $159M //
Source: https://www.businesswire.com/news/home/20210301005442/en/Hologic-Acquires-European-Molecular-Diagnostic-Company-Diagenode-for-Approximately-159-Million